Zosuquidar, also known as LY-335979, is a potent P-glycoprotein (P-gp) inhibitor, which binds with high affinity to P-glycoprotein and inhibits P-glycoprotein-mediated multidrug resistance (MDR). P-glycoprotein, encoded by the MDR-1 gene, is a member of the ATP-binding cassette superfamily of transmembrane transporters and prevents the intracellular accumulation of many natural product-derived cytotoxic agents.
Zosuquidar 3HCl (LY335979, RS 33295-198, D06387) is a potent modulator of P-glycoprotein-mediated multi-drug resistance with Ki of 60 nM in a cell-free assay. Phase 3.
P-glycoprotein Related Products:
Elacridar; Glibenclamide; Tariquidar; Selamectin; Atazanavir; Des(benzylpyridyl) Atazanavir; Valspodar